Physician profile
Robert K Snyder
NPI 1598762981
$1,624.54
in general payments reported to CMS, 2019-2025
13 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $150 · 2021: $46.69 · 2022: $119 · 2023: $290 · 2024: $176 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.41 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $522.13 | 2022-2025 | Jublia, Arazlo, Cabtreo |
| Janssen Biotech, INC. | $331.33 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Regeneron Healthcare Solutions, INC. | $176.61 | 2019-2020 | |
| Genentech USA, INC. | $125.91 | 2019-2021 | |
| Abbvie INC. | $114.50 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $110.15 | 2020 | |
| Sun Pharmaceutical Industries INC. | $99.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Alimera Sciences, INC. | $35.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $13.02 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.